IS8353A - Lyfjablanda sem felur í sér lantanefnasambönd - Google Patents

Lyfjablanda sem felur í sér lantanefnasambönd

Info

Publication number
IS8353A
IS8353A IS8353A IS8353A IS8353A IS 8353 A IS8353 A IS 8353A IS 8353 A IS8353 A IS 8353A IS 8353 A IS8353 A IS 8353A IS 8353 A IS8353 A IS 8353A
Authority
IS
Iceland
Prior art keywords
pharmaceutical composition
lanthanum compounds
lanthanum
compounds
pharmaceutical
Prior art date
Application number
IS8353A
Other languages
English (en)
Other versions
IS2893B (is
Inventor
Christine Ferdinando Josephine
Paul Haslam Robert
Anna Trespidi Laura
Original Assignee
Shire Holdings Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34221462&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8353(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Holdings Ag filed Critical Shire Holdings Ag
Publication of IS8353A publication Critical patent/IS8353A/is
Publication of IS2893B publication Critical patent/IS2893B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS8353A 2003-08-26 2006-03-15 Lyfjasamsetning sem inniheldur lantanefnasambönd IS2893B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49756003P 2003-08-26 2003-08-26
US51707803P 2003-11-05 2003-11-05
PCT/CA2004/001563 WO2005018651A1 (en) 2003-08-26 2004-08-26 Pharmaceutical formulation comprising lanthanum compounds

Publications (2)

Publication Number Publication Date
IS8353A true IS8353A (is) 2006-03-15
IS2893B IS2893B (is) 2014-09-15

Family

ID=34221462

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8353A IS2893B (is) 2003-08-26 2006-03-15 Lyfjasamsetning sem inniheldur lantanefnasambönd

Country Status (29)

Country Link
US (2) US7465465B2 (is)
EP (4) EP2133084B1 (is)
JP (2) JP4896719B2 (is)
KR (1) KR100830764B1 (is)
CN (1) CN1871018B (is)
AT (2) ATE460169T1 (is)
AU (2) AU2004266050B2 (is)
BR (1) BRPI0413394A8 (is)
CA (1) CA2536959C (is)
CY (2) CY1110241T1 (is)
CZ (1) CZ17621U1 (is)
DE (2) DE202004021169U1 (is)
DK (5) DK1660104T3 (is)
EA (2) EA200970709A1 (is)
ES (4) ES2532389T3 (is)
FI (1) FI7568U1 (is)
HK (1) HK1084338A1 (is)
HU (2) HUE029382T2 (is)
IL (2) IL173755A0 (is)
IS (1) IS2893B (is)
MX (1) MXPA06002257A (is)
NO (1) NO342559B1 (is)
NZ (1) NZ545633A (is)
PL (4) PL1660104T3 (is)
PT (4) PT1660104E (is)
SG (1) SG145765A1 (is)
SI (4) SI2792363T1 (is)
WO (1) WO2005018651A1 (is)
ZA (1) ZA200602213B (is)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
ATE499943T1 (de) * 2001-04-23 2011-03-15 Shire Int Licensing Bv Verwendung von lanthankarbonat zur prävention von nierensteinleiden
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
DE202004021169U1 (de) 2003-08-26 2007-03-01 Shire Holdings Ag Pharmazeutische Formulierung, die Lanthanverbindungen enthält
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
AU2005269362B2 (en) * 2004-07-27 2010-08-12 Shire Pharmaceuticals, Inc. Method of treating hyperphosphataemia using lanthanum hydroxycarbonate
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
CA2583548A1 (en) * 2004-10-15 2006-04-27 Altairnano, Inc. Phosphate binder with reduced pill burden
ITME20040015A1 (it) 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
EP1698233A1 (en) * 2005-03-01 2006-09-06 Bayer HealthCare AG Reduction of digestibility of phosphorus in animal nutrition
EP1947960A4 (en) * 2005-08-17 2009-05-06 Altairnano Inc COMPOSITIONS AND METHODS FOR TREATING HYPERPHOSPHATEMIA IN DOMESTIC ANIMALS
US20080058250A1 (en) * 2005-08-17 2008-03-06 Allison Wren Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
CN100398112C (zh) * 2006-03-24 2008-07-02 辽宁诺康生物制药有限责任公司 一种治疗血磷酸盐过多症的药物及其制备方法
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
CA2694516A1 (en) * 2007-07-31 2009-02-05 Cargill, Incorporated Direct compressible dextrose
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
TWI468167B (zh) 2007-11-16 2015-01-11 威佛（國際）股份有限公司 藥學組成物
WO2009118760A2 (en) * 2008-03-26 2009-10-01 Matrix Laboratories Limited Lanthanum composition
ES2433076T3 (es) * 2009-01-21 2013-12-09 Mylan Inc. Formulaciones disgregables de carbonato de lantano
WO2010106557A2 (en) * 2009-03-20 2010-09-23 Panacea Biotec Limited Stable pharmaceutical formulations comprising anhydrous lanthanum carbonate and process for preparation thereof
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
WO2011051968A2 (en) * 2009-10-26 2011-05-05 Alkem Laboratories Ltd. Pharmaceutical compositions of lanthanum carbonate and process for the preparation thereof
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
US8961917B2 (en) 2010-05-12 2015-02-24 Spectrum Pharmaceuticals, Inc. Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
EP2441436A1 (de) 2010-10-13 2012-04-18 Fresenius Medical Care Deutschland GmbH Phosphatbinderformulierung zur einfachen Einnahme
US8263119B2 (en) * 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
US8697132B2 (en) 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
CN103127041A (zh) * 2012-02-23 2013-06-05 南京卡文迪许生物工程技术有限公司 含有醋酸镧的药物组合物及其制备方法和用途
DE102012209411A1 (de) * 2012-06-04 2013-12-05 Fim Biotech Gmbh Mineralische Verbindung zur Reduzierung von anorganischen Phosphaten, insbesondere im Rahmen einer Nierenersatztherapie
CN104473963B (zh) * 2014-12-24 2017-10-10 厦门科明达科技有限公司 稀土化学药碳酸镧咀嚼片的制备方法
JP2016147827A (ja) * 2015-02-12 2016-08-18 株式会社三和化学研究所 炭酸ランタン水和物を含有する医薬製剤
US10058569B2 (en) 2015-06-24 2018-08-28 Lupin Limited Lanthanum carbonate compositions
JP6093829B1 (ja) * 2015-10-02 2017-03-08 バイエル薬品株式会社 ランタン化合物を含む医薬組成物
JP6623753B2 (ja) * 2015-12-28 2019-12-25 ニプロ株式会社 炭酸ランタンを含む口腔内崩壊錠
CN107213126B (zh) * 2017-05-17 2020-06-23 西安棣加生物科技有限公司 一种3d打印技术制备治疗高磷血症的口腔速崩片的方法
CN108969497A (zh) * 2018-10-12 2018-12-11 沈阳华泰药物研究有限公司 一种碳酸镧片剂组合物及其制备方法
EP4061340A4 (en) * 2019-11-21 2023-08-09 Santa Farma Ilaç Sanayi A.S. ORAL SOLID PHARMACEUTICAL COMPOSITIONS WITH LANTANHANE CARBONATE OCTAHYDRATE
CN113244179B (zh) * 2021-05-21 2023-01-13 浙江仟源海力生制药有限公司 一种稳定性好的碳酸镧片剂及其制备方法和其应用
US20230123099A1 (en) * 2021-10-15 2023-04-20 Fertin Pharma A/S Dextrose tablets with improved mouthfeel
CN115813867B (zh) * 2022-12-01 2024-05-24 山东齐都药业有限公司 碳酸镧冻干片及其制备方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54155675A (en) * 1978-05-30 1979-12-07 Matsushita Electronics Corp Small-sized fluorescent lamp
JPH06705B2 (ja) 1985-12-19 1994-01-05 旭化成工業株式会社 リン酸イオンの固定化剤
US4822594A (en) * 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
JPS6485088A (en) 1987-06-19 1989-03-30 Takeda Chemical Industries Ltd Production of 2-keto-l-gulonic acid
US4877735A (en) * 1987-06-19 1989-10-31 Takeda Chemical Industries, Ltd. Process for producing 2-keto-L-gulonic acid
DE3724188C2 (de) 1987-07-17 1995-05-18 Heinz Dr Gries Metallhaltige Oligosaccharid-Polysulfate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel
EP0620728B1 (en) * 1992-01-13 1997-01-08 Pfizer Inc. Preparation of tablets of increased strength
SI0760648T1 (en) 1994-05-20 2002-04-30 Janssen Pharmaceutica N.V. Chewable flubendazole tablets for companion animals
CA2128199C (en) * 1994-07-15 1997-02-04 Bernard Charles Sherman Stable solid pharmaceutical compositions containing enalapril maleate
JP3591886B2 (ja) 1994-09-05 2004-11-24 シーシーアイ株式会社 希土類元素集積微生物
GB9506126D0 (en) * 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US6074672A (en) 1996-06-28 2000-06-13 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Powdered cosmetic compositions containing silicone elastomers
GB9720061D0 (en) * 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
GB9816899D0 (en) * 1998-08-05 1998-09-30 Boots Co Plc Therapeutic agents
US6270790B1 (en) * 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
JP2000173537A (ja) * 1998-09-29 2000-06-23 Toshiba Lighting & Technology Corp 低圧水銀蒸気放電灯および照明装置
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6160016A (en) * 1999-12-22 2000-12-12 Wisconsin Alumni Research Foundation Phosphorus binder
GB0008392D0 (en) 2000-04-05 2000-05-24 Unilever Plc Process for the production of a deodorant or antiperspirant product
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
US20020057059A1 (en) * 2000-07-28 2002-05-16 Kazuhisa Ogishi Fluorescent lamp, self-ballasted fluorescent lamp and lighting apparatus
JP2002047210A (ja) 2000-08-04 2002-02-12 Nihon Medi Physics Co Ltd 尿路結石防止用組成物
DE60136096D1 (de) 2000-12-19 2008-11-20 Yakult Honsha Kk Externe hautpräparate und verfahren zu ihrer herstellung
JP4612183B2 (ja) 2000-12-27 2011-01-12 株式会社ヤクルト本社 皮膚外用組成物及びその製造方法
JP4612180B2 (ja) 2000-12-19 2011-01-12 株式会社ヤクルト本社 皮膚外用剤
US20020122823A1 (en) 2000-12-29 2002-09-05 Bunick Frank J. Soft tablet containing dextrose monohydrate
WO2002058699A1 (en) * 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
ATE499943T1 (de) * 2001-04-23 2011-03-15 Shire Int Licensing Bv Verwendung von lanthankarbonat zur prävention von nierensteinleiden
GB0201607D0 (en) * 2002-01-24 2002-03-13 Gamlen Michael J D Formulation for the administration of medicinal substances
ATE425744T1 (de) * 2002-04-29 2009-04-15 Supernus Pharmaceuticals Inc Pharmazeutische formulierungen mit verbesserter bioverfugbarkeit
WO2003094933A2 (en) * 2002-05-08 2003-11-20 Shire Holding Ag Use of lanthanum for the treatment of hypercalcemia and bone metastasis
US20040161474A1 (en) 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
AU2003282867A1 (en) * 2002-10-22 2004-05-13 Genzyme Corporation Amine polymers for promoting bone formation
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
DE202004021169U1 (de) 2003-08-26 2007-03-01 Shire Holdings Ag Pharmazeutische Formulierung, die Lanthanverbindungen enthält
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7335795B2 (en) * 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7449605B2 (en) * 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7608674B2 (en) 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7545784B2 (en) * 2004-02-11 2009-06-09 Yahoo! Inc. System and method for wireless communication between previously known and unknown users
US8192758B2 (en) * 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US8282960B2 (en) * 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US7854924B2 (en) * 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
GB2430367B (en) 2004-03-30 2009-08-05 Ilypsa Inc Ion binding polymers and uses thereof
AU2005269362B2 (en) * 2004-07-27 2010-08-12 Shire Pharmaceuticals, Inc. Method of treating hyperphosphataemia using lanthanum hydroxycarbonate
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
WO2009118760A2 (en) 2008-03-26 2009-10-01 Matrix Laboratories Limited Lanthanum composition

Also Published As

Publication number Publication date
DK2133084T3 (en) 2015-04-13
EP2792363A1 (en) 2014-10-22
EP1660104B1 (en) 2010-03-10
CN1871018B (zh) 2011-11-02
EP2133084A3 (en) 2010-02-03
JP4896719B2 (ja) 2012-03-14
AT9809U1 (de) 2008-04-15
CY1118211T1 (el) 2017-06-28
SI2133084T1 (sl) 2015-07-31
DK200600252U4 (da) 2007-11-23
PL2133084T3 (pl) 2015-08-31
US20050079135A1 (en) 2005-04-14
EP2172205B1 (en) 2014-06-18
CY1110241T1 (el) 2015-01-14
PT2172205E (pt) 2014-07-17
FIU20060387U0 (fi) 2006-09-22
PL1660104T3 (pl) 2010-08-31
PL2792363T3 (pl) 2017-01-31
CN1871018A (zh) 2006-11-29
FI7568U1 (fi) 2007-07-17
DK2172205T3 (da) 2014-07-14
BRPI0413394A (pt) 2006-10-17
EP1660104A1 (en) 2006-05-31
EP1660104A4 (en) 2006-10-18
ES2532389T3 (es) 2015-03-26
IL235371B (en) 2018-08-30
AU2009202429B2 (en) 2012-03-22
JP2007503400A (ja) 2007-02-22
ATE460169T1 (de) 2010-03-15
DE602004025950D1 (de) 2010-04-22
PL2172205T3 (pl) 2015-01-30
PT2792363T (pt) 2016-09-26
KR20060118420A (ko) 2006-11-23
NO342559B1 (no) 2018-06-18
DK200600252U1 (da) 2007-01-12
EP2792363B1 (en) 2016-06-29
BRPI0413394A8 (pt) 2016-03-08
SI1660104T1 (sl) 2010-08-31
NZ545633A (en) 2009-07-31
SG145765A1 (en) 2008-09-29
HUE029382T2 (en) 2017-02-28
CA2536959A1 (en) 2005-03-03
EP2133084B1 (en) 2015-02-18
EA200970709A1 (ru) 2010-04-30
EA200600479A1 (ru) 2006-08-25
DE202004021169U1 (de) 2007-03-01
HUE024906T2 (en) 2016-02-29
PT2133084E (pt) 2015-04-16
EA012798B1 (ru) 2009-12-30
ZA200602213B (en) 2009-04-29
ES2343354T3 (es) 2010-07-29
US20090017133A1 (en) 2009-01-15
WO2005018651A1 (en) 2005-03-03
KR100830764B1 (ko) 2008-05-20
SI2792363T1 (sl) 2016-11-30
ES2592803T3 (es) 2016-12-01
EP2172205A1 (en) 2010-04-07
AU2004266050B2 (en) 2009-06-18
SI2172205T1 (sl) 2014-10-30
MXPA06002257A (es) 2006-05-17
DK2792363T3 (da) 2016-09-26
DK1660104T3 (da) 2010-06-21
CZ17621U1 (cs) 2007-06-25
ES2478258T3 (es) 2014-07-21
NO20061347L (no) 2006-05-15
IS2893B (is) 2014-09-15
CA2536959C (en) 2011-08-02
US7465465B2 (en) 2008-12-16
HK1084338A1 (en) 2006-07-28
AU2004266050A1 (en) 2005-03-03
PT1660104E (pt) 2010-06-15
IL173755A0 (en) 2006-07-05
JP2010248247A (ja) 2010-11-04
AU2009202429A1 (en) 2009-07-09
EP2133084A2 (en) 2009-12-16

Similar Documents

Publication Publication Date Title
IS8353A (is) Lyfjablanda sem felur í sér lantanefnasambönd
IS8460A (is) Lyfjafræðileg samsetning sem inniheldur kvetíapín
IS8287A (is) Lyfjablanda sem felur í sér levóþýroxínnatríum
IS2946B (is) Lyfjablanda sem felur í sér andrógen
NO20052952D0 (no) Farmasoytisk sammensetning som innbefatter mikropartikler
IS8351A (is) Lyfjaafurðir sem fela í sér bisfosfónöt
EP1648364A4 (en) PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATION
DK1587478T3 (da) Farmaceutisk sammensætning
HK1084670A1 (en) Pharmaceutical compositions comprising cabbinochreme type compounds
IS7458A (is) Stöðug lyfjablanda sem inniheldur þátt VIII
EP1699458A4 (en) PHARMACEUTICAL COMPOSITION
IS7219A (is) Lyfjablanda sem inniheldur (R) -bíkalútamíð
GB0300885D0 (en) Pharmaceutical composition
IS7581A (is) Lyfjasamsetning
GB0306933D0 (en) Pharmaceutical composition
ZA200509741B (en) Pharmaceutical composition comprising cyclic smatostin analogues
NO20044164L (no) Farmasoytiske sammensetninger
GB0310361D0 (en) Pharmaceutical compound
EE200300378A (et) Farmatseutiline kompositsioon
GB0307864D0 (en) Pharmaceutical composition
GB0307862D0 (en) Pharmaceutical composition
IS7384A (is) Stöðug lyfjablanda sem felur í sér torsemíð afbrigði II
DOP2002000508A (es) Composición farmaceutica
ITMI20020926A1 (it) Composizioni farmaceutiche riepitelizzanti
GB0313595D0 (en) Pharmaceutical compound